TY - JOUR T1 - The use of online visual analogue scales in idiopathic pulmonary fibrosis JF - European Respiratory Journal JO - Eur Respir J DO - 10.1183/13993003.01531-2021 SP - 2101531 AU - Moor, Catharina C. AU - Mostard, Remy L.M. AU - Grutters, Jan C. AU - Bresser, Paul AU - Wijsenbeek, Marlies S. Y1 - 2021/01/01 UR - //www.qdcxjkg.com/content/early/2021/07/21/13993003.01531-2021.abstract N2 - Idiopathic pulmonary fibrosis (IPF) is a progressive, deadly disease with a major impact on the lives of patients [1]. Symptom burden and quality of life (QoL) can be assessed with patient-reported outcome measures (PROMs). In the past decade, PROM use was increasingly advocated to capture the impact of treatments and interventions on patients” symptoms and wellbeing [2]. PROMS are often lengthy, on paper, and with difficult scoring systems, hampering direct use in clinical practice [2]. Thus, there is a need for easy-to-use PROMs in IPF and other ILDs, both for clinical trials and daily practice.FootnotesThis manuscript has recently been accepted for publication in the European Respiratory Journal. It is published here in its accepted form prior to copyediting and typesetting by our production team. After these production processes are complete and the authors have approved the resulting proofs, the article will move to the latest issue of the ERJ online. Please open or download the PDF to view this article.Conflict of interest: C.C. Moor reports grants and lecture payments from Boehringer Ingelheim, outside the submitted work.Conflict of interest: Rémy Mostard reports personal fees from Boehringer Ingelheim, personal fees from Roche, personal fees from Galapagos, outside the submitted work.Conflict of interest: Jan Grutters and Paul Bresser have nothing to disclose.Conflict of interest: Marlies Wijsenbeek reports grant payments to institution from the Netherlands Organization for Health Research and Development during the conduct of the study; grant, contract payments, consulting fees, lecture payments and advisory board payments to institution from Boehringer Ingelheim, Hoffman la Roche, The Netherlands Organisation for Health Research and Development, The Dutch Lung Foundation, The Dutch Pulmonary Fibrosis Patient Association, The Thorax Foundation, ErasmusMC, Sarcoidosis.nl, Galapagos, Bristol Myers Squibb, Galecto, Respivant, Novartis, Savara; support for attending meetings from Boehringer Ingelheim and Hoffman la Roche; unpaid leadership roles: Secretary of the Idiopathic Interstitial Pneumonia group of the European Respiratory Society, Member of the board of the Netherlands Respiratory Society, Member of the scientific advisory board of the European Idiopathic Pulmonary Fibrosis and related disorders federation, Chair of the educational committee of the European Reference Network for rare Lung Diseases, Advisory board of the Dutch Lungfibrosis and Sarcoidosis patient associations, outside the submitted work. ER -